tetano
Editor, Senior Moderator
Mol Cell Probes
. 2021 Sep 21;101771.
doi: 10.1016/j.mcp.2021.101771. Online ahead of print.
Reverse transcription recombinase-aided amplification assay for rapid detection of the influenza A(H1N1)pdm09 H275Y mutation that confers oseltamivir resistance
Jun Li[SUP] 1 [/SUP], Zi Yang[SUP] 2 [/SUP], Ling-Feng Mao[SUP] 3 [/SUP], Ren-Hua Chen[SUP] 4 [/SUP], Xin-Fen Yu[SUP] 1 [/SUP], Xu-Hui Yang[SUP] 4 [/SUP], Guo-Zhong Zhang[SUP] 1 [/SUP], Hao-Qiu Wang[SUP] 1 [/SUP], Shu-Chang Chen[SUP] 1 [/SUP], Gang Zhao[SUP] 5 [/SUP]
Affiliations
Abstract
The emergence of the influenza A(H1N1)pdm09 virus with the NA-H275Y mutation, which confers oseltamivir resistance, must be monitored, especially in patients undergoing neuraminidase inhibitor treatment. In this study, we developed a reverse transcription recombinase-aided amplification assay that has high sensitivity (detection limit: 1.0×10[SUP]1[/SUP] copies/μL) and specificity for detecting the oseltamivir-resistant H275Y mutation; the assay is performed within 30 minutes at a constant temperature of 39 degrees Celsius using an isothermal device. This method is suitable for the clinical application of targeted testing, thereby providing technical support for precision medicine in individual drug applications for patients with severe infection or immunosuppression.
Keywords: A(H1N1)pdm09; Influenza virus; resistance mutation; reverse-transcription recombinase-aided amplification.
. 2021 Sep 21;101771.
doi: 10.1016/j.mcp.2021.101771. Online ahead of print.
Reverse transcription recombinase-aided amplification assay for rapid detection of the influenza A(H1N1)pdm09 H275Y mutation that confers oseltamivir resistance
Jun Li[SUP] 1 [/SUP], Zi Yang[SUP] 2 [/SUP], Ling-Feng Mao[SUP] 3 [/SUP], Ren-Hua Chen[SUP] 4 [/SUP], Xin-Fen Yu[SUP] 1 [/SUP], Xu-Hui Yang[SUP] 4 [/SUP], Guo-Zhong Zhang[SUP] 1 [/SUP], Hao-Qiu Wang[SUP] 1 [/SUP], Shu-Chang Chen[SUP] 1 [/SUP], Gang Zhao[SUP] 5 [/SUP]
Affiliations
- PMID: 34560257
- DOI: 10.1016/j.mcp.2021.101771
Abstract
The emergence of the influenza A(H1N1)pdm09 virus with the NA-H275Y mutation, which confers oseltamivir resistance, must be monitored, especially in patients undergoing neuraminidase inhibitor treatment. In this study, we developed a reverse transcription recombinase-aided amplification assay that has high sensitivity (detection limit: 1.0×10[SUP]1[/SUP] copies/μL) and specificity for detecting the oseltamivir-resistant H275Y mutation; the assay is performed within 30 minutes at a constant temperature of 39 degrees Celsius using an isothermal device. This method is suitable for the clinical application of targeted testing, thereby providing technical support for precision medicine in individual drug applications for patients with severe infection or immunosuppression.
Keywords: A(H1N1)pdm09; Influenza virus; resistance mutation; reverse-transcription recombinase-aided amplification.